K. Prabhash

Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized, double-blind safety and efficacy trial.

James R. Rigas, M. Schuster, Branislav Milovanović et al. · Journal of Clinical Oncology · 2010 · 45 citations

Medicine, Oncology, Pharmacotherapy +16

Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcripts

S Polampalli, Anuradha Choughule, Noriyuki Negi et al. · Genetics and Molecular Research · 2008 · 38 citations · Full text

Life Sciences, Hematology, Molecular Biology +17

A year of anaplastic large cell kinase testing for lung carcinoma: Pathological and technical perspectives

S. Desai, AS Shah, K. Prabhash et al. · Indian Journal of Cancer · 2013 · 33 citations

Medicine, Oncology, Pathology +17

ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial.

M. Schuster, James R. Rigas, Branislav Milovanović et al. · Journal of Clinical Oncology · 2010 · 30 citations

Medicine, Hematology, Oncology +17

LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen

Siow Ming Lee, Christian Schulz, K. Prabhash et al. · Annals of Oncology · 2022 · 21 citations · Full text

Medicine, Oncology, Pharmacology +10